[go: up one dir, main page]

DK200401589A - Oprenset basisk human-FGF, fremgangsmåde til fremstilling af denne, samt farmaceutisk sammensætning indeholdende denne - Google Patents

Oprenset basisk human-FGF, fremgangsmåde til fremstilling af denne, samt farmaceutisk sammensætning indeholdende denne Download PDF

Info

Publication number
DK200401589A
DK200401589A DK200401589A DKPA200401589A DK200401589A DK 200401589 A DK200401589 A DK 200401589A DK 200401589 A DK200401589 A DK 200401589A DK PA200401589 A DKPA200401589 A DK PA200401589A DK 200401589 A DK200401589 A DK 200401589A
Authority
DK
Denmark
Prior art keywords
fgf
dna sequence
prodn
factors
fibroblast growth
Prior art date
Application number
DK200401589A
Other languages
English (en)
Inventor
John C Fiddes
Judith A Abraham
Original Assignee
California Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200401589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/809,163 external-priority patent/US5439818A/en
Application filed by California Biotechnology Inc filed Critical California Biotechnology Inc
Publication of DK200401589A publication Critical patent/DK200401589A/da
Application granted granted Critical
Publication of DK176067B1 publication Critical patent/DK176067B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Description

Patentkrav 1. Oprenset basisk human-FGF som er opnåelig ved udtrykkelse af en DNA-sekvens omfattende codonsekvensen, der er nummereret 16-146 i Figur 4, i en rekombinant bakteriel værtscelle. 2. Protein ifølge krav 1, i hvilket DNA-sekvensen omfatter codonsekvensen, der er nummereret 1-146 i Figur 4. 3. Protein ifølge krav 2, i hvilket DNA-sekvensen omfatter codonsekvensen, der er nummereret (-9) eller (-8) til 146 i Figur 4. 4. Protein ifølge ethvert af kravene 1 til 3, i hvilket den bakterielle værtscelle er E.coli. 5. Fremgangsmåde til fremstilling af basisk human-FGF, hvilken fremgangsmåde omfatter udtrykkelse af en DNA-sekvens omfattende de codons, der er nummereret 16-146 i Figur 4, i en rekombinant bakteriel vært og genvinding af det basiske human-FGF. 6. Farmaceutisk sammensætning omfattende en effektiv mængde af det basiske human-FGF ifølge ethvert af kravene 1 til 4 i en tilblanding med mindst én farmaceutisk acceptabel excipiens.
DK200401589A 1985-09-12 2004-10-18 Oprenset basisk human-FGF, fremgangsmåde til fremstilling af denne, samt farmaceutisk sammensætning indeholdende denne DK176067B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77552185A 1985-09-12 1985-09-12
US06/809,163 US5439818A (en) 1985-09-12 1985-12-16 DNA encoding human recombinant basic fibroblast growth factor
US86938286A 1986-05-30 1986-05-30
DK198702418A DK175795B1 (da) 1985-09-12 1987-05-12 Rekombinant eller syntetisk DNA-sekvens, der koder for et FGF-protein, vektor, der indeholder DNA-sekvensen og en rekombinant værtscelle, der indeholder DNA-sekvensen eller vektoren

Publications (2)

Publication Number Publication Date
DK200401589A true DK200401589A (da) 2004-10-18
DK176067B1 DK176067B1 (da) 2006-03-06

Family

ID=27419719

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198702418A DK175795B1 (da) 1985-09-12 1987-05-12 Rekombinant eller syntetisk DNA-sekvens, der koder for et FGF-protein, vektor, der indeholder DNA-sekvensen og en rekombinant værtscelle, der indeholder DNA-sekvensen eller vektoren
DK200401589A DK176067B1 (da) 1985-09-12 2004-10-18 Oprenset basisk human-FGF, fremgangsmåde til fremstilling af denne, samt farmaceutisk sammensætning indeholdende denne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198702418A DK175795B1 (da) 1985-09-12 1987-05-12 Rekombinant eller syntetisk DNA-sekvens, der koder for et FGF-protein, vektor, der indeholder DNA-sekvensen og en rekombinant værtscelle, der indeholder DNA-sekvensen eller vektoren

Country Status (11)

Country Link
EP (2) EP0248819B2 (da)
JP (3) JPH0789936B2 (da)
AT (2) ATE105868T1 (da)
AU (1) AU590006B2 (da)
CA (1) CA1341640C (da)
DE (2) DE3689845T3 (da)
DK (2) DK175795B1 (da)
ES (1) ES2001967A6 (da)
IE (1) IE66689B1 (da)
IL (1) IL80022A (da)
WO (1) WO1987001728A1 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US5401832A (en) * 1984-12-24 1995-03-28 Merck & Co., Inc. Brain derived and recombinant acidic fibroblast growth factor
US5026839A (en) * 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
DE3689921T2 (de) * 1985-12-17 1994-09-22 Synergen Inc Menschlicher plazentarer angiogenischer Faktor, geeignet für die Reizung der Kapillarsynthese, der Endothelzellprotease, der DNS-Synthese und der Absiedlung.
US5827826A (en) * 1986-03-03 1998-10-27 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compositions of human endothelial cell growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US5552528A (en) 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
EP0246753B1 (en) * 1986-04-22 1994-07-13 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
US5474982A (en) * 1986-08-13 1995-12-12 Zymogenetics, Inc. PDGF analogs and methods of use
WO1988005465A1 (en) * 1987-01-16 1988-07-28 Amgen Inc. Production of fibroblast growth factor
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
EP0288687B1 (en) * 1987-03-03 1994-12-28 Takeda Chemical Industries, Ltd. Monoclonal antibody, hybridoma, their production and use thereof
EP0364481A4 (en) * 1987-06-18 1992-01-22 Monash University Growth factors
AU611614B2 (en) * 1987-06-18 1991-06-13 Monash University Growth factors
DE3721081A1 (de) * 1987-06-26 1989-01-19 Progen Biotechnik Gmbh Dna-sequenz, die codiert fuer ein zellteilungsfoerderndes polypeptid, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses polypeptids
NZ226543A (en) * 1987-10-22 1992-02-25 Merck & Co Inc Recombinant mutant acidic fibroblast growth factor
US5312911A (en) * 1987-10-22 1994-05-17 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
JPH02504468A (ja) * 1987-11-24 1990-12-20 アムジエン・インコーポレーテツド 繊維芽細胞成長因子のアナログ
EP0326907A1 (en) * 1988-01-26 1989-08-09 Takeda Chemical Industries, Ltd. Polypeptide, DNA and its use
WO1989007944A1 (en) * 1988-02-24 1989-09-08 American National Red Cross Device for site directed neovascularization and method for same
GB2223496B (en) * 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
GB2223497B (en) * 1988-08-08 1992-04-01 British Bio Technology Synthetic gene encoding human beta endothelial cell growth factor
GB2223495B (en) * 1988-08-08 1992-05-20 British Bio Technology Synthetic gene encoding basic fibroblast growth factor
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
EP0441886B1 (en) * 1988-11-04 1996-08-21 Chiron Corporation Expression and processing of acetylated fgf's in yeast
US5656458A (en) * 1988-11-04 1997-08-12 Chiron Corporation Expression and processing of amino terminus acetylated FGF's in yeast
US5464943A (en) * 1989-04-26 1995-11-07 Takeda Chemical Industries, Ltd. DNA encoding glycosylated FGF and production thereof
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
IT1237795B (it) * 1989-12-22 1993-06-17 Erba Carlo Spa Fattori di crescita fibroblastici per l'uso nella prevenzione e nel trattamento di infezioni virali.
US5143829A (en) * 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
JPH047617A (ja) * 1990-04-26 1992-01-13 Canon Inc 電子機器
JP3135138B2 (ja) * 1990-12-19 2001-02-13 科研製薬株式会社 骨疾患治療剤
US6833354B1 (en) 1990-12-19 2004-12-21 Kaken Pharmaceutical Co., Ltd. Agent for the treatment of bone diseases
GR1002610B (el) * 1991-01-02 1997-02-20 Johnson & Johnson Consumer Products Inc. Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
AU1194092A (en) * 1991-02-06 1992-09-07 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
ATE139700T1 (de) * 1991-02-15 1996-07-15 Takeda Chemical Industries Ltd Mit einem zellwachstumsfaktor bewirkte anregung von wachstum im knocheninneren
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
AU673659B2 (en) * 1991-11-25 1996-11-21 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
CA2108277A1 (en) * 1992-02-14 1993-08-15 Mitsuru Watanuki Preparation for the therapy of respiratory tract diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
WO1996040726A1 (en) 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
WO1999066797A1 (en) 1998-06-22 1999-12-29 Worden Charles E Enriched platelet wound healant
ATE434440T1 (de) * 1998-09-03 2009-07-15 Novartis Vaccines & Diagnostic Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6649072B2 (en) 2001-11-16 2003-11-18 Robert Brandt Method for producing autologous platelet-rich plasma
CN1671836B (zh) 2002-06-18 2012-02-08 卫材R&D管理有限公司 用于基因治疗的原代培养脂肪细胞
WO2005087257A1 (ja) * 2004-03-16 2005-09-22 Kaken Pharmaceutical Co., Ltd. 架橋ゼラチンゲルを担体とする軟骨組織修復治療剤
ES2318915B1 (es) * 2004-12-29 2010-02-16 Universidad De Salamanca Uso de fgf-2 en celulas precursoras de oligodendrocitos.
WO2007072857A1 (ja) 2005-12-22 2007-06-28 Hoya Corporation 眼鏡レンズのレンズ面切削加工装置、レンズ面切削加工方法および眼鏡レンズ
EP2353547B1 (en) 2008-06-26 2018-01-17 Nobelpharma Co., Ltd. Agent for regenerating tympanic membrane or external auditory canal
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CN104946656B (zh) * 2015-06-08 2018-08-17 吉林省农业科学院 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法
CN110151977B (zh) * 2019-05-29 2022-11-29 新乡医学院 一种保护aFGF蛋白药物稳定性和活性的方法
WO2021097186A1 (en) 2019-11-13 2021-05-20 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions

Also Published As

Publication number Publication date
IE862432L (en) 1987-03-12
ES2001967A6 (es) 1988-07-01
EP0593065B1 (en) 2002-08-21
IE950301L (en) 1987-03-12
AU590006B2 (en) 1989-10-26
DE3650774T2 (de) 2003-05-28
EP0248819B2 (en) 2000-08-30
IE66689B1 (en) 1996-01-24
JPH09118695A (ja) 1997-05-06
AU6375586A (en) 1987-04-07
DE3689845D1 (de) 1994-06-23
EP0248819A4 (en) 1989-02-23
DK241887A (da) 1987-05-12
ATE222602T1 (de) 2002-09-15
EP0593065A1 (en) 1994-04-20
CA1341640C (en) 2014-09-16
DK175795B1 (da) 2005-02-21
EP0248819B1 (en) 1994-05-18
JPH0767659A (ja) 1995-03-14
DE3650774D1 (de) 2002-09-26
DK176067B1 (da) 2006-03-06
JP2761513B2 (ja) 1998-06-04
IL80022A (en) 1993-06-10
ATE105868T1 (de) 1994-06-15
JPS63500843A (ja) 1988-03-31
DE3689845T2 (de) 1994-09-01
EP0248819A1 (en) 1987-12-16
WO1987001728A1 (en) 1987-03-26
DE3689845T3 (de) 2001-11-15
IL80022A0 (en) 1986-12-31
DK241887D0 (da) 1987-05-12
JPH0789936B2 (ja) 1995-10-04
JP2619208B2 (ja) 1997-06-11

Similar Documents

Publication Publication Date Title
DK200401589A (da) Oprenset basisk human-FGF, fremgangsmåde til fremstilling af denne, samt farmaceutisk sammensætning indeholdende denne
US5149792A (en) Platelet-derived growth factor B chain analogs
US5824505A (en) Vectors, transformed cells and process for the preparation of hirudin
US4677064A (en) Human tumor necrosis factor
EP0458959B1 (en) Novel platelet-derived growth factor b chain analogs and method for homogeneous production thereof
DK305885A (da) Tumornecrosefaktor og derivater og mutantformer deraf, frem. til frems. deraf, frem. til isolering deraf fra en blanding med andre proteiner,praeparater deraf, dna som koder derfor, dna'en inkorporeret i en replicerbar vektor og celle transformeret dermed
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
FI102190B1 (fi) Menetelmä pesäkkeitä stimuloivan tekijä-1:n uusien muotojen valmistamiseksi ja siinä käytettäviä DNA-sekvenssejä, vektoreita, ilmentämisjärjestelmiä ja rekombinanttisoluja
BR9307510A (pt) Molécula de ácido nucleico purificada e isolada plasmídeo recombinante adaptado para transformação de hospedeiro vector recombinante adaptado para transformação de célula hospedeira proteína purificada e isolada proteína de membrana externa d15 peptídio sintético molécula quimérica composição imunogênica e anti-soro ou anticorpo
DK0786009T3 (da) Fremgangsmåde til bakteriel fremstilling af heterologe polypeptider med disulphidbindinger
AU629185B2 (en) Cell growth inhibitory factor
EP0072541A3 (en) Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
Ishii et al. Full active baculovirus-expressed human monocyte chemoattractant protein 1 with the intact N-terminus
Shabo et al. Target‐cell specificity of hematopoietic regulatory proteins for different clones of myeloid leukemic cells: Two regulators secreted by krebs carcinoma cells
EP0672684A1 (en) Novel megakaryocyte colony stimulating factor and production thereof
AU651330B2 (en) Novel proteins with oncostatin M activity and process for their preparation
Kikyo et al. Purification of a cell growth factor from a human lung cancer cell line: its relationship with ferritin
DK200401111A (da) Fremgangsmåde til fremstilling af et humant pluripotent granulocyt kolonistimulerende faktorprodukt
ISHII et al. a Pharmaceutical Discovery Research Laboratories, and Biotechnology
IT1201407B (it) Procedimento di preparazione di un estratto antigenico totale batterico da usarsi per la produzione di vaccini
IE904732A1 (en) Novel proteins with oncostatin m activity and process for¹their preparation

Legal Events

Date Code Title Description
PUP Patent expired